Takeda Pharmaceutical Company Limited

Cardurion Pharmaceuticals, LLC

Yoshito Terao

Rei Okamoto

Yasushi Hattori

Tatsuki Koike

Tsuneo Oda

Takahiro Sugimoto

Yasutaka Hoashi

Junya Shirai

Norihito Tokunaga

Xiaolun Wang

Yuichi Kajita

Yoshiteru Ito

Keisuke Imamura

Yuhei Miyanohana

Tomohiro Okawa

Nicholas Scorah

Keiko Kakegawa

Minoru Yoshida

John S Tyhonas

Edcon Chang

Phong H Vu

Tohru Miyazaki

Terufumi Takagi

Mark Sabat

Yasufumi Miyamoto

Koichiro Fukuda

Kohei Takeuchi

Akito Shibuya

Joanne Miura

Zenyu Shiokawa

Haixia Wang

Yuta Tanaka

Yoichi Nishikawa

Nobuyuki Matsunaga

Takafumi Yukawa

Lily Kwok

Naoki Miyamoto

Mallareddy Komandla

Yasuhisa Kohara

Takeshi Yoshikawa

Angie Vassar

Takashi Nakahata

Taiichi Ohra

Hiroki Takahagi

Tracy Duong

Dilhumar Uyghur

Paul Tanis

Masanori Kawasaki

Takehiro Hirano

Takeshi Yamasaki

Tsuneo Yasuma

Nobuyuki Takakura

Hideki Furukawa

Atsuko Ochida

Yoshihide Tomata

Shizuo Kasai

Shuji Kitamura

Yoshihiro Banno

Minoru Ikoma

Kousuke Hidaka

Masashi Takahashi

Sachie Morimoto

Toshiki Murata

Ryoma Hara

Kei Masuda

Shinichi Masada

Jun Chiba

Matthew H McNeill

Matthew H McNiell

The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the description, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.

Heterocyclic compound

The present invention provides a compound having a CaMKII inhibitory action, which is expected to be useful as an agent for the prophylaxis or treatment of cardiac diseases (particularly catecholaminergic polymorphic ventricular tachycardia, postoperative atrial fibrillation, heart failure, fatal arrhythmia) and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification,or a salt thereof.

Substituted amines for treating cardiac diseases

The present invention aims to provide a heterocyclic compound having an IP6K inhibitory action and expected to be useful as a prophylactic or therapeutic agent for&#x2014;diseases such as cardiac failure, diabetes and the like. A compound represented by the formula (I): wherein each symbol is as defined in the SPECIFICATION, or a salt thereof has an IP6K inhibitory action and is expected to be useful as a prophylactic or therapeutic agent for diseases such as cardiac failure, diabetes and the like. 

IP6K inhibitors

The present invention provides a compound having a CaMKII inhibitory action, which is expected to be useful as an agent for the prophylaxis or treatment of cardiac diseases (particularly catecholaminergic polymorphic ventricular tachycardia, postoperative atrial fibrillation, heart failure, fatal arrhythmia) and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.

The present invention provides a compound having a GOAT inhibitory action, which is useful for the prophylaxis or treatment of obesity and the like, and has superior efficacy. The present invention is a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof. 

Aromatic ring compound

The present invention relates to apoptosis signal-regulating kinase 1 ('ASK1') inhibiting compounds of the formula wherein the variables are as defined herein. The invention also relates to pharmaceutical compositions, kits and articles of manufacture comprising such compounds; methods and intermediates useful for making the compounds; and methods of using said compounds.

Apoptosis signal-regulating kinase 1 inhibitors

The present invention provides an indole derivative having a melanin-concentrating hormone receptor antagonistic action, which is useful as an agent for the prophylaxis or treatment of obesity and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.

Indole derivative

The present invention relates to apoptosis signal-regulating kinase 1 ('ASK1') . inhibiting compounds of the formula wherein the variables are as defined herein. The invention also relates to pharmaceutical compositions, kits and articles of manufacture comprising such compounds, to methods and intermediates useful for making the compounds, and to methods of using the compounds.

Substituted N-(pyrazolo[1,5-a]pyrimidin-5-yl)amides as inhibitors of apoptosis signal-regulating kinase 1

Growing community of inventors

Kanagawa, Japan

Yoshito Terao